Article Sidebar

Published: 2026-03-31
Abstract Views: 0
DOI: https://doi.org/10.52163/yhc.v67i3.4657
Issue
Vol. 67 No. 3
Section
Articles
How to Cite
Liễu, L. T., Sơn, B. T., & Thanh, H. H. T. (2026). CLINICAL AND PARACLINICAL CHARACTERISTICS OF OCULAR ADNEXAL MARGINAL ZONE B-CELL LYMPHOMA . Vietnam Journal of Community Medicine, 67(3). https://doi.org/10.52163/yhc.v67i3.4657

CLINICAL AND PARACLINICAL CHARACTERISTICS OF OCULAR ADNEXAL MARGINAL ZONE B-CELL LYMPHOMA

Le Thi Lieu1, Bui Thanh Son1, Ha Huy Thien Thanh1
1 Central Eye Hospital

Main Article Content

Abstract

Objective: To describe the clinical and paraclinical characteristics of patients with ocular adnexal marginal zone B-cell lymphoma (OAL).


Methods: A descriptive retrospective and prospective study was conducted on 16 patients aged 18 and older, diagnosed with ocular marginal zone lymphoma via histopathology and immunohistochemistry from January 2023 to October 2023 at Vietnam National Eye Hospital.


Results: The mean age was 59,5 ± 8,7 years; the male-to-female ratio was 1,7. The most common reason for admission was self-detected tumor (56,25%). Typical clinical symptoms included palpable mass (87,5%), proptosis (62,5%) and ptosis (25%). The most frequent locations were orbital soft tissue (62,5%) and conjunctiva (50%). Most patients were in the early stage (Ann Arbor stage I: 62,5%; AJCC stage T2: 81,25%). LDH and Beta2M levels were 100% low; 50% of patients had a low IPI score. Immunohistochemistry showed 100% expression of CD20 and 87,5% for BCL2; the mean Ki67 index was low (7,5%).


Conclusion: Ocular adnexal marginal zone lymphoma is common in middle-aged individuals, with a male predominance observed in this study. The disease usually presents at an early stage with a favorable prognosis, consistent with the indolent B-cell marginal zone immunohistochemical profile.

Article Details

Keywords

Ocular adnexal marginal zone lymphoma, clinical, subclinical, immunohistochemistry.

References

1. Ferreri AJM, Sassone M, Miserocchi E, Govi S, Cecchetti C, Corti ME, et al. Treatment of MALT lymphoma of the conjunctiva with intralesional rituximab supplemented with autologous serum. Blood Adv. 2020;4(6):1013-9.
2. Kirkegaard MM, Rasmussen PK, Coupland SE, Esmaeli B, Finger PT, Graue GF, et al. Conjunctival Lymphoma--An International Multicenter Retrospective Study. JAMA ophthalmology. 2016;134(4):406-14.
3. Letschert JG, González González D, Oskam J, Koornneef L, van Dijk JD, Boukes R, et al. Results of radiotherapy in patients with stage I orbital non-Hodgkin's lymphoma. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 1991;22(1):36-44.
4. Richards H, Ramsden C, Naidoo R, Yvon C, Jacob E, Mohamedbhai S. Ocular adnexal lymphomas: a review. Expert Review of Ophthalmology. 2017;12(2):133-48.
5. Meunier J, Lumbroso-Le Rouic L, Vincent-Salomon A, Dendale R, Asselain B, Arnaud P, et al. Ophthalmologic and intraocular non-Hodgkin's lymphoma: a large single centre study of initial characteristics, natural history, and prognostic factors. Hematological oncology. 2004;22(4):143-58.
6. Jenkins C, Rose GE, Bunce C, Cree I, Norton A, Plowman PN, et al. Clinical features associated with survival of patients with lymphoma of the ocular adnexa. Eye (London, England). 2003;17(7):809-20.
7. Zanni M, Moulin-Romsee G, Servois V, Validire P, Bénamor M, Plancher C, et al. Value of 18FDG PET scan in staging of ocular adnexal lymphomas: a large single-center experience. Hematology (Amsterdam, Netherlands). 2012;17(2):76-84.
8. Decaudin D, de Cremoux P, Vincent-Salomon A, Dendale R, Rouic LL-L. Ocular adnexal lymphoma: a review of clinicopathologic features and treatment options. Blood. 2006;108(5):1451-60.
9. Jeon Y-W, Yang H-J, Choi B-O, Jung S-E, Park K-S, O J-H, et al. Comparison of Selection and Long-term Clinical Outcomes Between Chemotherapy and Radiotherapy as Primary Therapeutic Modality for Ocular Adnexal MALT Lymphoma. eClinicalMedicine. 2018;4:32-42.